Nuklearmedizin. Nuclear medicine最新文献

{"title":"Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck.","authors":"Sophie C Siegmund, Sebastian E Serfling, Takahiro Higuchi, Andreas Buck, Martin Canis, Christoph A Reichel, Rudolf A Werner","doi":"10.1055/a-2800-7670","DOIUrl":"https://doi.org/10.1055/a-2800-7670","url":null,"abstract":"<p><p>This review aims to explore the evolving field of theranostics in oncology, focusing on its potential application to head and neck squamous cell carcinoma (HNSCC). Specifically, it examines the integration of molecular imaging and radionuclide therapy in the context of theranostics.A comprehensive review of current literature was conducted to evaluate the state-of-the-art theranostic approaches in HNSCC. The review includes an analysis of established and emerging molecular targets relevant to HNSCC, as well as the potential for future theranostic developments.The integration of theranostic principles into head and neck oncology is gaining momentum, with increasing interest in novel targets in the context of theranostics. Although [¹⁸F]FDG PET/CT still remains the dominant imaging modality in HNSCC, the application of novel radiotracers for imaging and radionuclide therapy holds considerable promise.Theranostics represents a promising future for head and neck oncology, offering the potential for personalized, biology-driven diagnostic and therapeutic strategies. While many emerging approaches are still under investigation, the combination of molecular imaging and targeted radionuclide therapy may significantly enhance the treatment of HNSCC, providing more precise and effective patient care in the future.1.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial Perfusion SPECT 2024 in Germany: Results of the 10th Survey.","authors":"Oliver Lindner, Matthias Gutberlet, Wolfgang Burchert, Thorsten Derlin, Christoph Rischpler","doi":"10.1055/a-2738-2589","DOIUrl":"10.1055/a-2738-2589","url":null,"abstract":"<p><p>This paper presents the results of the 10^th survey of myocardial perfusion SPECT (MPS) from the year 2024.A total of 198 questionnaires were evaluated, comprising 115 practices (PR), 57 hospitals (HO) and 26 university hospitals (UH). The results of the previous survey 2021 are shown in squared brackets.MPS data from 128.707 [133.057] patients (-3.3%) with 125.175 [131.868] stress and 102.903 [106.546] rest MPS were analysed. A comparison with official data revealed that 53% of all MPS were recorded. From 2018 to 2024, official data showed an increase in MPS every year. In 2024, on average, 650 [610] MPS patients (+7%) were examined in each department. Of the participating departments, 69% [74%] reported an increase or no changes in their patient numbers. As always ambulatory care cardiologists represented the major referral group (68% [69%]). Pharmacological stress was performed more frequently than ergometry (43% [42%]). Regadenoson was mostly used. The use of the different protocols remained almost unchanged. Two-day protocols were predominantly applied (49% [49%]). Multi-head cameras were used in (56% [58%] of the departments and SPECT-CT systems in (31% [28%]). Attenuation correction was performed in 35% [33%] of all MPS. 95% [89%] of all stress, 93% [88%] of all rest and 92% [87%] of all stress and rest scan were acquired as gated SPECT. 84% [72%] of the departments performed scoring by default. The proportion of departments not scoring decreased to 4% [13%].The MPS 2024 survey indicates that the long-term positive development of MPS imaging is continuing. The procedural and technical details of MPS imaging demonstrate a high level of conformity with guidelines, with a slight improvement observed from 2021 to 2024.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"30-38"},"PeriodicalIF":1.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145598541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioiodine Therapy Unit as a \"No-Care\" Ward - A First Experience Report.","authors":"Martin Freesmeyer, Christian Kühnel, Eike Voigt, Tabea Nikola Schmidt, Philipp Seifert, Falk Gühne, Thomas Winkens","doi":"10.1055/a-2733-4579","DOIUrl":"10.1055/a-2733-4579","url":null,"abstract":"<p><p>Nuclear medicine landscape has been changing over the past decade due to the rise of radioligand therapies. However, patients receiving radioiodine therapy for benign thyroid disease still account for approx. one third of the patients on a regular nuclear medicine ward. A substantial part of these patients are hospitalized for radiation protection only and do not require nursing staff. This report aims at describing the implementation of a \"no-care\" nuclear medicine ward with medical students as staff. We report on the training process, patient and student satisfaction as well as the impact and strengths of this concept.A separated nuclear medicine ward (10 beds) was established at a university hospital in Germany. After specific training, two students were assigned per working shift in a regular three-shift-system. Patients were evaluated according to predefined inclusion and exclusion criteria. Patients and students answered two separate surveys, assessing the satisfaction with the concept.172/319 (53.9%) of the patients met the inclusion criteria. The \"no-care\" ward was opened six times between April 2024 and June 2025 and the duration was between 10 and 20 days. 101 patients were treated using I-131 sodium iodine, achieving 68.5 DRG relative units. Patient satisfaction survey revealed very high positive response rates. 27 medical students were assigned to the \"no-care\" ward. The majority of students stated a positive effect on overall medical knowledge and workflow understanding in a hospital.Using medical students as staff on a \"no-care\" nuclear medicine ward is feasible and safe. In view of nursing staff shortage, this concept might contribute to adaptive caring in nuclear medicine therapies after careful patient selection.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"22-29"},"PeriodicalIF":1.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12880862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145598501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of hepatic alveolar echinococcosis:18F-FDG-PET activity compared to the Echinococcus multilocularis Ulm Ultrasound Classification.","authors":"Wolfgang Kratzer, Sibylle Steinkellner, Dennis Skotnik, Lynn Peters, Beate Gruener, Nina Eberhardt","doi":"10.1055/a-2744-4139","DOIUrl":"10.1055/a-2744-4139","url":null,"abstract":"<p><p>Alveolar echinococcosis (AE) is a rare, potentially fatal zoonosis with highly heterogeneous morphology. This study compares AE lesions in B-scan ultrasound, categorized according to the Echinococcus multilocularis Ulm Classification - Ultrasound (EMUC-US), with the maximum standardized uptake value (SUVmax) in 18F-Fluorodeoxyglucose Positron-Emission-Tomography (18F-FDG-PET/CT). 18F-FDG-PET/CT is the gold standard for evaluating disease activity, with SUVmax as the key parameter indirectly reflecting AE lesion activity.Retrospective analysis of data from the German National Echinococcosis Database. A total of 121 patients with 18F-FDG-PET/CT and B-scan ultrasound (US) between 2018-2019 were included. Based on EMUC-US, AE liver lesions were compared with the corresponding SUVmax in PET/CT. Additionally, SUV ratios (SUVTLR=tumor SUVmax/liver SUVmean) were calculated.The mean SUVmax, regardless of the EMUC-US subtype, was 6.0 ± 3.3 (range: 2.4-18.0). SUVmax comparison between subtypes shows significant differences (p<0.001). The highest SUVmax and SUVTLR were measured for the pseudocystic pattern with a mean of 9.2 ± 3.5 (range: 4.1-18.0). In contrast, the metastasis-like pattern yielded 3.7 ± 0.9 (range: 2.4-5.8) and the lowest SUVTLR. An SUVmax of 6.1 ± 3.3 (range: 2.6-16.8) was measured for the hailstorm pattern and 5.8 ± 2.2 (range: 3.6-10.4) for the hemangioma-like pattern.The results show significant differences between specific US patterns and the corresponding SUVmax. Lesions with very high or low SUV correlate with characteristic morphological patterns. Hence, in clinical practice B-scan can be a valuable bedside tool for assessing certain lesions. For evaluating inflammatory activity, 18F-FDG-PET/CT remains the method of choice.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"4-12"},"PeriodicalIF":1.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12880861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145656802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Tumor Localization is Associated with Progression-free Survival and Overall Survival after Selective-Internal-Radio-Therapy of Liver Metastases in Metastatic Colorectal Cancer.","authors":"Lucia Lutat, Barbara Kreppel, Milka Marinova, Ingo G H Schmidt-Wolf, Carsten Meyer, Markus Essler","doi":"10.1055/a-2738-2390","DOIUrl":"10.1055/a-2738-2390","url":null,"abstract":"<p><p>This retrospective study aimed to investigate whether the differing biology of right-sided primary tumors (RSP) and left-sided primary tumors (LSP) in metastatic colorectal cancer (mCRC) affects survival outcomes following selective internal radiation therapy (SIRT).A cohort of 140 mCRC patients with liver metastases treated with SIRT between 2009 and 2016 was analyzed. Patients were stratified by tumor localization (RSP: proximal colon; LSP: distal colon and rectum), clinical, histopathological, and molecular data, were collected. Survival outcomes (OS and PFS) were evaluated using Kaplan-Meier analysis. Cox regression analysis identified independent predictors of survival, and subgroup analyses examined differences between RSP and LSP patients.Of the patients, 80.7% had LSP, and 19.3% had RSP. RSP patients demonstrated more aggressive tumor biology, with a higher frequency of poorly differentiated tumors (G3), extrahepatic metastases and K-RAS mutations. Median OS was significantly longer for LSP patients (7.0 months) compared to RSP patients (4.0 months, p<0.005). Similarly, PFS was longer for LSP patients (3.0 months) than for RSP patients (1.6 months, p<0.032). Multivariable Cox regression analysis revealed that K-RAS mutation (HR 3.345, p=0.017), N2 lymph node involvement (HR 2.458, p=0.015), and RSP localization (HR 0.338, p=0.001) were independently associated with poor survival.This study demonstrates that right-sided tumor localization, K-RAS mutation, and N2 lymph node involvement are key predictors of poor survival following SIRT in mCRC patients. RSP tumors, with distinct molecular and clinical profiles, exhibit shorter median OS and PFS after SIRT compared to LSP tumors.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"13-21"},"PeriodicalIF":1.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of CD68+ Macrophages and FoxP3+ Regulatory T Cells in Neuroendocrine Tumors.","authors":"Barbara Kreppel, Jana Fink, Christine Sanders, Anna Scherping, Oliver Hommerding, Milka Marinova, Ingo G H Schmidt-Wolf, Georg Feldmann, Maria Angeles Gonzalez-Carmona, Azin Jafari, Markus Essler, Glen Kristiansen","doi":"10.1055/a-2739-5187","DOIUrl":"10.1055/a-2739-5187","url":null,"abstract":"<p><p>Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies characterized by variable immune microenvironment. This study aimed to analyze the infiltration of NETs by CD68⁺ tumor-associated macrophages (TAMs) and FoxP3⁺ regulatory T cells (Tregs) using Qupath software for semi-automated histopathological quantificationThirty-two patients with resected NETs were included. CD68 and FoxP3 expression were assessed by immunohistochemistry followed by automated cell detection and spatial analysis.The mean percentage of CD68⁺ cells was 0.35%, with no significant differences between pancreatic and gastrointestinal NETs. FoxP3⁺ cells were less frequent (mean: 0.06%), with higher levels in gastrointestinal NETs compared to pancreatic NETs (p < 0.05). Kaplan-Meier analysis revealed that CD68⁺ cells showed a trend to positive correlation with progression-free survival (PFS) and overall survival (OS). Thereby, patients exceeding a 0.1% CD68⁺ cell threshold exhibited longer survival (PFS: not reached vs. 106 months). In contrast, FoxP3⁺ cells showed a trend to inverse correlation with survival; patients with >0.05% FoxP3⁺ cells had shorter PFS (36 months vs. 147 months) and OS (180 months vs. not reached). Multivariate Cox regression identified N-stage as the sole predictor of OS. CD68⁺ TAM density was not associated with other clinical parameters, while FoxP3⁺ cell infiltration correlated significantly with venous invasion and advanced N- and M-stages.These findings highlight the potential prognostic relevance of immune cell infiltration in NETs and underscore the utility of Qupath for quantifying immune markers in histopathological analyses. The contrasting roles of CD68⁺ TAMs and FoxP3⁺ Tregs in the NET microenvironment warrant further exploration to inform immunotherapeutic strategies.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"39-47"},"PeriodicalIF":1.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145656749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intermittent hydrarthrosis of both knees successfully treated with radiosynoviorthesis using 90Y-Citrat.","authors":"Ali Afshar-Oromieh, Nasir Gözlügöl, Theresa Schreder, Stefan Kuchen, Axel Rominger, Keivan Daneshvar","doi":"10.1055/a-2710-7068","DOIUrl":"https://doi.org/10.1055/a-2710-7068","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"64 6","pages":"327-328"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experimental approach for optimizing dose regimen of 68Ga-DOTATATE PET/CT for neuroendocrine tumor (NET) imaging in current high sensitivity scanners: Phantom and Patient Study.","authors":"Abbas Monsef, Fatemeh Saboktakin, Fatemeh Sadeghi, Mohammadreza Elhaie, Mohsen Beheshti, Peyman Sheikhzadeh","doi":"10.1055/a-2710-7001","DOIUrl":"10.1055/a-2710-7001","url":null,"abstract":"<p><p>This study aimed to determine the optimized scan time and injected activity regimen for clinical ⁶⁸Ga DOTATATE PET/CT in neuroendocrine tumor imaging through an experimental approach without using machine learning techniques.A NEMA PET body phantom was used with Ga-⁶⁸ to simulate a 9:1 sphere-to-background ratio. PET data were acquired on a high-sensitivity scanner at various scan times (15-300 s/bed). For each scan time, coefficient of variation (COV) and contrast-to-noise ratio (CNR) were calculated. The minimum scan time (T_min) needed to meet the Rose Criterion (CNR > 5) for the smallest sphere was identified. This T_min was then applied to patient scans with neuroendocrine tumors (originally acquired at 120 s/bed) to evaluate image quality and determine an optimized activity regimen for clinical ⁶⁸Ga-DOTATATE PET imaging.Phantom experiments showed that a COV_max of 20% is the highest acceptable noise level for detecting the smallest lesions, corresponding to a minimum scan time of about 1 minute per bed position. Patient image analysis confirmed that all tumors visible at routine scan times were still detectable at this minimum duration. This supports the use of a lower activity regimen (~1 MBq/kg), which can reduce patient radiation exposure compared to the standard 1.85 MBq/kg protocol.This work demonstrated that scan time and activity for ⁶⁸Ga-DOTATATE NET imaging can be significantly minimized without compromising image interpretation and quantification.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"64 6","pages":"341-351"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!","authors":"Islam A S Elhelf, Michael Clemenshaw","doi":"10.1055/a-2729-8686","DOIUrl":"10.1055/a-2729-8686","url":null,"abstract":"<p><p>In 2018, the Food and Drug Administration (FDA) approved lutetium-177 (¹⁷⁷Lu) DOTATATE (LUTATHERA, Advanced Accelerator Applications [Novartis]) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Since then, ¹⁷⁷Lu DOTATATE has been increasingly used as a treatment option for NETs. Less than 5 years later, in March 2022, ¹⁷⁷Lu vipivotide tetraxetan (PLUVICTO, Advanced Accelerator Applications) received FDA approval for the treatment of prostatespecific membrane antigen-positive castration-resistant metastatic prostate cancer. Both drugs are excellent examples of viable radiotheranostic therapies. As more radiotheranostic agents and applications get adopted in clinical practice, interventional radiologists are likely to get exposed to this field in a way or another. In this article, we discuss the fundamentals of radiotheranostic therapy and explore the expanding role interventional radiology (IR) is expected to play as an essential partner in modern oncology practice.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"64 6","pages":"352-355"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging-based characterization of tumoral heterogeneity for personalized cancer treatment.","authors":"Florian Haag, Alexander Hertel, Hishan Tharmaseelan, Mustafa Kuru, Verena Haselmann, Christoph Brochhausen, Stefan O Schönberg, Matthias F Froelich","doi":"10.1055/a-2729-9288","DOIUrl":"https://doi.org/10.1055/a-2729-9288","url":null,"abstract":"<p><p>With personalized tumor therapy, understanding and addressing the heterogeneity of malignant tumors is becoming increasingly important. Heterogeneity can be found within one lesion (intralesional) and between several tumor lesions emerging from one primary tumor (interlesional). The heterogeneous tumor cells may show a different response to treatment due to their biology, which in turn influences the outcome of the affected patients and the choice of therapeutic agents. Therefore, both intra- and interlesional heterogeneity should be addressed at the diagnostic stage. While genetic and biological heterogeneity are important parameters in molecular tumor characterization and in histopathology, they are not yet addressed routinely in medical imaging. This article summarizes the recently established markers for tumor heterogeneity in imaging as well as heterogeneous/mixed response to therapy. Furthermore, a look at emerging markers is given. The ultimate goal of this overview is to provide comprehensive understanding of tumor heterogeneity and its implications for radiology and for communication with interdisciplinary teams in oncology. · Tumor heterogeneity can be described within one lesion (intralesional) or between several lesions (interlesional).. · The heterogeneous biology of tumor cells can lead to a mixed therapeutic response and should be addressed in diagnostics and the therapeutic regime.. · Quantitative image diagnostics can be enhanced using AI, improved histopathological methods, and liquid profiling in the future..</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"64 6","pages":"356-366"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}